 AUSTIN, Texas, Aug. 5, 2021 PRNewswire -- Aeglea BioTherapeutics, Inc. Nasdaq:AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2021, and reviewed recent corporate updates and program highlights. 2021 is proving to be a pivotal year for Aeglea. 